Xingsheng Hu,Lin Wang,Lin Lin,Yuankai Shi. Progress in clinical trial of histone deacetylase (HDAC) inhibitors for non-small cell lung cancers. Oncol Transl Med, 2014, 13: 185-188.
Progress in clinical trial of histone deacetylase (HDAC) inhibitors for non-small cell lung cancers
  
View Full Text  View/Add Comment  Download reader
KeyWord:
Author NameAffiliation
Xingsheng Hu Beijing Key Laboratory of Clinical Research on Molecular-targeted Antitumor Agents, Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical college (CAMS & PUMC), Beijing 10021, China 
Lin Wang Beijing Key Laboratory of Clinical Research on Molecular-targeted Antitumor Agents, Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical college (CAMS & PUMC), Beijing 10022, China 
Lin Lin Beijing Key Laboratory of Clinical Research on Molecular-targeted Antitumor Agents, Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical college (CAMS & PUMC), Beijing 10023, China 
Yuankai Shi Beijing Key Laboratory of Clinical Research on Molecular-targeted Antitumor Agents, Department of Medical Oncology, Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical college (CAMS & PUMC), Beijing 10024, China 
Hits: 5271
Download times: 5988
Abstract:
      Histone deacetylase (HDAC) inhibitors, which represent a structurally diverse group of molecules, have emerged as a novel therapeutic class of molecules with significant anticancer potential. Vorinostat and romidepsin, known as the first generation of HDAC inhibitors, were approved in the United States for the treatment of T-cell lymphomas. Preliminary activity of HDAC inhibitors has also been observed in non-small cell lung cancer (NSCLC) in combination with the existing treatment regimens, of which is the focus of the current review.
Close